|Cahn, Daniel - SYNGENTA AG, OXNARD, CA|
|Leppla, Norman - UNIV. OF FLORIDA|
Submitted to: Entomological Society of America Proceedings
Publication Type: Abstract Only
Publication Acceptance Date: December 15, 2006
Publication Date: December 15, 2006
Citation: Streett, D.A., Cahn, D., Leppla, N.C. 2006. Private/Public Sector Partnerships & Technology Transfer. Entomological Society of America Proceedings. Meeting Abstract. Technical Abstract: The bottom line in the commercialization of a biological control agent (bca) is economics. Can a product that is effective against a target pest be developed cheaply enough to compete with existing controls, especially chemicals to return and acceptable profit on the investment? Market considerations are critical to the development of any bca product. Technical constraints towards development of a commercial bca product that should be considered include: 1) effectiveness of a bca in the market, 2) techncial problems with mass production, and 3) formulation of a viable product. The National Biological Control Laboratory (NBCL) has a strong research program in these three areas constraining the commercialization of a bca product and could work with a company through the Cooperative Research and Development Agreement (CRADA) process to develop the bca product.